Patients with HIV had similar treatment outcomes to patients without HIV when treated for mpox with an antiviral drug called tecovirimat, according to a new study.
Nearly 90% of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.
Big Red Ventures (BRV), Cornell’s early-stage venture capital fund, showcased the student-run portfolio and highlighted 2022-23 investments during the Annual Meeting on April 20 at Cornell Tech.
How do you solve a problem like a massive decommissioned nuclear power plant only 35 miles north of New York City with no clear future use? This semester, an architecture option studio at the Cornell Gensler Family AAP NYC Center is tackling this very question, imagining an evolution for the facility rather than a demolition.
The first-year class of students in the Milstein Program in Technology and Humanity are finishing up their community projects and looking forward to their summer in New York City.
The Yang-Tan WorkABILITY Incubator, recently launched through the ILR School’s Center for Applied Research on Work, will support innovative applied research projects and collaborations.
Targeting part of a key antiviral pathway may one day offer a new therapeutic approach to deterring or delaying cognitive decline, according to preclinical research led by Weill Cornell Medicine scientists.
